<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>COSOPT- dorzolamide hydrochloride and timolol maleate solution </strong><br>Merck Sharp &amp; Dohme Corp.<br></p></div>
<h1>COSOPT<span class="Sup">®</span><br> (dorzolamide hydrochloride-timolol maleate ophthalmic solution) <br>Sterile Ophthalmic Solution</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_14622707-65f5-47ac-ad65-c68ae85f6d7e"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">COSOPT<span class="Sup">®</span> (dorzolamide hydrochloride-timolol maleate ophthalmic solution) is the combination of a topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent. </p>
<p>Dorzolamide hydrochloride is described chemically as: (4<span class="Italics">S-</span><span class="Italics">trans</span>)-4-(ethylamino)-5,6-dihydro-6-methyl-4<span class="Italics">H</span>-thieno[2,3-<span class="Italics">b</span>]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride. Dorzolamide hydrochloride is optically active. The specific rotation is:</p>
<p>                [α]          25°C                      (C=1, water) = ~ -17°.</p>
<p>                              405 nm</p>
<p>Its empirical formula is C<span class="Sub">10</span>H<span class="Sub">16</span>N<span class="Sub">2</span>O<span class="Sub">4</span>S<span class="Sub">3</span>•HCl and its structural formula is:</p>
<div class="Figure"><img alt="chemical structure for dorzolamide hydrochloride" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-01.jpg"></div>
<p>Dorzolamide hydrochloride has a molecular weight of 360.91. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol. </p>
<p>Timolol maleate is described chemically as: (-)-1-(<span class="Italics">tert</span>-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:</p>
<p>         [α]               25°C            in 1N HCl (C = 5) = -12.2° (-11.7° to -12.5°).</p>
<p>                            405 nm</p>
<p> Its molecular formula is C<span class="Sub">13</span>H<span class="Sub">24</span>N<span class="Sub">4</span>O<span class="Sub">3</span>S•C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and its structural formula is:</p>
<div class="Figure"><img alt="chemical structure for timolol maleate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-02.jpg"></div>
<p>Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature. </p>
<p>COSOPT is supplied as a sterile, isotonic, buffered, slightly viscous, aqueous solution. The pH of the solution is approximately 5.65, and the osmolarity is 242-323 mOsM. Each mL of COSOPT contains 20 mg dorzolamide (22.26 mg of dorzolamide hydrochloride) and 5 mg timolol (6.83 mg timolol maleate). Inactive ingredients are sodium citrate, hydroxyethyl cellulose, sodium hydroxide, mannitol, and water for injection. Benzalkonium chloride 0.0075% is added as a preservative.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_e8ca79a0-413f-4e68-9e45-24fdcc5f614d"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_c0276bee-513a-4f03-a1fa-9c83c2238164"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">COSOPT is comprised of two components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>. </p>
<p>Dorzolamide hydrochloride is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> ions with subsequent reduction in sodium and fluid transport. Timolol maleate is a beta<span class="Sub">1</span> and beta<span class="Sub">2</span> (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. The combined effect of these two agents administered as COSOPT b.i.d. results in additional intraocular pressure reduction compared to either component administered alone, but the reduction is not as much as when dorzolamide t.i.d. and timolol b.i.d. are administered concomitantly (see <a href="#i4i_clinical_studies_id_bcd21399-1b52-4c7c-b845-62a429cdcf26">Clinical Studies</a>).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_8f82114d-513f-4aff-8a91-a472f3d428db"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics/Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7491b4e-cc07-4b7e-ab72-ef5237c7469d"></a><a name="section-2.2.1"></a><p></p>
<h3>Dorzolamide Hydrochloride</h3>
<p class="First">When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, drug and metabolite concentrations in RBCs and plasma and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of binding to CA-II. The parent drug forms a single N-desethyl metabolite, which inhibits CA-II less potently than the parent drug but also inhibits CA-I. The metabolite also accumulates in RBCs where it binds primarily to CA-I. Plasma concentrations of dorzolamide and metabolite are generally below the assay limit of quantitation (15nM). Dorzolamide binds moderately to plasma proteins (approximately 33%). </p>
<p>Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine. After dosing is stopped, dorzolamide washes out of RBCs nonlinearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about four months. </p>
<p>To simulate the systemic exposure after long-term topical ocular administration, dorzolamide was given orally to eight healthy subjects for up to 20 weeks. The oral dose of 2 mg b.i.d. closely approximates the amount of drug delivered by topical ocular administration of dorzolamide 2% t.i.d. Steady state was reached within 8 weeks. The inhibition of CA-II and total carbonic anhydrase activities was below the degree of inhibition anticipated to be necessary for a pharmacological effect on renal function and respiration in healthy individuals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b0e7ced-5757-4496-8b05-79f7dff20b1b"></a><a name="section-2.2.2"></a><p></p>
<h3>Timolol Maleate</h3>
<p class="First">In a study of plasma drug concentrations in six subjects, the systemic exposure to timolol was determined following twice daily topical administration of timolol maleate ophthalmic solution 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_bcd21399-1b52-4c7c-b845-62a429cdcf26"></a><a name="section-2.3"></a><p></p>
<h2>Clinical Studies </h2>
<p class="First">Clinical studies of 3 to 15 months duration were conducted to compare the IOP-lowering effect over the course of the day of COSOPT b.i.d. (dosed morning and bedtime) to individually and concomitantly administered 0.5% timolol (b.i.d.) and 2.0% dorzolamide (b.i.d. and t.i.d.). The IOP-lowering effect of COSOPT b.i.d. was greater (1-3 mmHg) than that of monotherapy with either 2.0% dorzolamide t.i.d. or 0.5% timolol b.i.d. The IOP-lowering effect of COSOPT b.i.d. was approximately 1 mmHg less than that of concomitant therapy with 2.0% dorzolamide t.i.d. and 0.5% timolol b.i.d. </p>
<p>Open-label extensions of two studies were conducted for up to 12 months. During this period, the IOP-lowering effect of COSOPT b.i.d. was consistent during the 12 month follow-up period.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_32f4f39a-5ca8-4463-9fab-08dbb02f841e"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">COSOPT is indicated for the reduction of elevated intraocular pressure in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT b.i.d. was slightly less than that seen with the concomitant administration of 0.5% timolol b.i.d. and 2.0% dorzolamide t.i.d. (see <a href="#i4i_clinical_studies_id_bcd21399-1b52-4c7c-b845-62a429cdcf26">CLINICAL PHARMACOLOGY, Clinical Studies</a>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_d8d6f93d-222f-434a-a8d6-88952c91a0f5"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">COSOPT is contraindicated in patients with (1) reactive airway disease; (2) bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; (3) a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; (4) severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (see <a href="#i4i_warnings_id_c8db6756-8ec1-49b4-91fe-9a0955ca3715">WARNINGS</a>); (5) <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>; (6) sino-atrial block; (7) second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>; (8) overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (see <a href="#i4i_warnings_id_c8db6756-8ec1-49b4-91fe-9a0955ca3715">WARNINGS</a>); (9) <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>; or (10) <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_c8db6756-8ec1-49b4-91fe-9a0955ca3715"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e46e5df-4427-4bac-aa3d-321b21817869"></a><a name="section-5.1"></a><p></p>
<h2>Systemic Exposure</h2>
<p class="First">COSOPT contains dorzolamide, a sulfonamide, and timolol maleate, a beta-adrenergic blocking agent; and although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides and/or systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and rarely <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in association with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, have been reported following systemic or ophthalmic administration of timolol maleate (see <a href="#i4i_contraindications_id_d8d6f93d-222f-434a-a8d6-88952c91a0f5">CONTRAINDICATIONS</a>). Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occur, discontinue the use of this preparation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3f36a7d-d5a1-492e-9642-12eb1e34b554"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span> and Cardiovascular Disease</h2>
<p class="First">Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure. </p>
<p>Because of the timolol maleate component, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> should be adequately controlled before beginning therapy with COSOPT. Patients with a history of cardiovascular disease, including <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, should be watched for signs of deterioration of these diseases, and pulse rates should be checked.</p>
<p>Due to its negative effect on conduction time, beta-blockers should be given with caution to patients with first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.</p>
<p><span class="Italics">In Patients Without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></span> continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, COSOPT should be discontinued. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3bbd68da-e4bd-4cad-ab2a-2c92cdbb5fde"></a><a name="section-5.3"></a><p></p>
<h2>Obstructive Pulmonary Disease</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, in which COSOPT is contraindicated [see <a href="#i4i_contraindications_id_d8d6f93d-222f-434a-a8d6-88952c91a0f5">CONTRAINDICATIONS</a>]) should, in general, not receive beta-blocking agents, including COSOPT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_123180d1-0201-491b-9cf8-4b37fdd51e68"></a><a name="section-5.4"></a><p></p>
<h2>Major Surgery</h2>
<p class="First">The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents. </p>
<p>If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f1055dc8-66f4-4003-bbee-b4c3abf3a59f"></a><a name="section-5.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a70e69c6-7d01-4054-afa2-b5ded77c432b"></a><a name="section-5.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-adrenergic blocking agents may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="vascular"></a><a name="section-5.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></h2>
<p class="First">Patients with severe peripheral circulatory disturbance/disorders (e.g., severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_41e1c7ae-eadf-494d-8840-20a6b1d2081f"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_be36cb4b-3e1c-4770-b6fb-352d0a707e87"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Dorzolamide has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl &lt;30 mL/min). Because dorzolamide and its metabolite are excreted predominantly by the kidney, COSOPT is not recommended in such patients. </p>
<p>Dorzolamide has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and should therefore be used with caution in such patients. </p>
<p>While taking beta-blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopy</span> or a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</p>
<p>In clinical studies, local ocular adverse effects, primarily <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and lid reactions, were reported with chronic administration of COSOPT. Many of these reactions had the clinical appearance and course of an allergic-type reaction that resolved upon discontinuation of drug therapy. If such reactions are observed, COSOPT should be discontinued and the patient evaluated before considering restarting the drug. (See <a href="#i4i_adverse_effects_id_6ca0070a-7ad0-4e21-8c0e-7e4444b01e66">ADVERSE REACTIONS</a>.) </p>
<p>The management of patients with acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> requires therapeutic interventions in addition to ocular hypotensive agents. COSOPT has not been studied in patients with acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">Choroidal detachment</span> after filtration procedures has been reported with the administration of aqueous suppressant therapy (e.g., timolol). </p>
<p>Beta-adrenergic blockade has been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>). Timolol has been reported rarely to increase <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in some patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or myasthenic symptoms. </p>
<p>There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. (See <a href="#i4i_info_patients_id_37e5b0ac-b5cb-40aa-8030-0458f87ae655">PRECAUTIONS, Information for Patients</a>.)</p>
<p>There is an increased potential for developing <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span> in patients with low endothelial cell counts. Precautions should be used when prescribing COSOPT to this group of patients.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_37e5b0ac-b5cb-40aa-8030-0458f87ae655"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients with reactive airway disease, bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, sino-atrial block, second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> should be advised not to take this product. (See <a href="#i4i_contraindications_id_d8d6f93d-222f-434a-a8d6-88952c91a0f5">CONTRAINDICATIONS</a>.) </p>
<p>COSOPT contains dorzolamide (which is a sulfonamide) and, although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration, including severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. Patients should be advised that if serious or unusual reactions or signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occur, they should discontinue the use of the product (see <a href="#i4i_warnings_id_c8db6756-8ec1-49b4-91fe-9a0955ca3715">WARNINGS</a>). </p>
<p>Patients should be advised that if they develop any ocular reactions, particularly <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and lid reactions, they should discontinue use and seek their physician's advice. </p>
<p>Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. </p>
<p>Patients should also be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions. (See <a href="#i4i_precautions_general_id_be36cb4b-3e1c-4770-b6fb-352d0a707e87">PRECAUTIONS, General</a>.)</p>
<p>Patients also should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), they should immediately seek their physician's advice concerning the continued use of the present multidose container. </p>
<p>If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart. </p>
<p>Patients should be advised that COSOPT contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of COSOPT.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_495f23a9-0cac-4e63-a958-764dba6d41fd"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Italics">Carbonic anhydrase inhibitors: </span> There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and COSOPT. The concomitant administration of COSOPT and oral carbonic anhydrase inhibitors is not recommended.</p>
<p><span class="Italics">Acid-base disturbances:</span> Although acid-base and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving COSOPT.</p>
<p><span class="Italics">Beta-adrenergic blocking agents:</span> Patients who are receiving a beta-adrenergic blocking agent orally and COSOPT should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.</p>
<p><span class="Italics">Calcium antagonists:</span> Caution should be used in the coadministration of beta-adrenergic blocking agents, such as COSOPT, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In patients with impaired cardiac function, coadministration should be avoided. </p>
<p><span class="Italics">Catecholamine-depleting drugs and parasympathomimetics:</span> Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs, such as reserpine, or parasympathomimetics drugs, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may result in <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
<p><span class="Italics">Digitalis, calcium antagonists, and other antiarrhythmics:</span> The concomitant use of beta-adrenergic blocking agents with digitalis, calcium antagonists, or other antiarrhythmics may have additive effects in prolonging atrioventricular conduction time. </p>
<p><span class="Italics">CYP2D6 inhibitors:</span> Potentiated systemic beta-blockade (e.g., decreased heart rate, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.</p>
<p><span class="Italics">Clonidine</span>:  Oral beta-adrenergic blocking agents may exacerbate the <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> which can follow the withdrawal of clonidine. There have been no reports of exacerbation of <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> with ophthalmic timolol maleate.</p>
<p><span class="Italics">Injectable Epinephrine: </span> (See <a href="#i4i_precautions_general_id_be36cb4b-3e1c-4770-b6fb-352d0a707e87">PRECAUTIONS, General, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></a>.)</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_917b7c5a-efab-429a-9718-dd33c4e84d00"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a two-year study of dorzolamide hydrochloride administered orally to male and female Sprague-Dawley rats, urinary bladder <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> were seen in male rats in the highest dosage group of 20 mg/kg/day (250 times the recommended human ophthalmic dose). <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">Papillomas</span> were not seen in rats given oral doses equivalent to approximately 12 times the recommended human ophthalmic dose. No treatment-related tumors were seen in a 21-month study in female and male mice given oral doses up to 75 mg/kg/day (~900 times the recommended human ophthalmic dose). </p>
<p>The increased incidence of urinary bladder <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> seen in the high-dose male rats is a class-effect of carbonic anhydrase inhibitors in rats. Rats are particularly prone to developing <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> in response to foreign bodies, compounds causing <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>, and diverse sodium salts. </p>
<p>No changes in bladder urothelium were seen in dogs given oral dorzolamide hydrochloride for one year at 2 mg/kg/day (25 times the recommended human ophthalmic dose) or monkeys dosed topically to the eye at 0.4 mg/kg/day (~5 times the recommended human ophthalmic dose) for one year. </p>
<p>In a two-year study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in male rats administered 300 mg/kg/day (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Similar differences were not observed in rats administered oral doses equivalent to approximately 14,000 times the maximum recommended human ophthalmic dose. </p>
<p>In a lifetime oral study of timolol maleate in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> and mammary adenocarcinomas in female mice at 500 mg/kg/day, (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose), but not at 5 or 50 mg/kg/day (approximately 700 or 7,000, respectively, times the systemic exposure following the maximum recommended human ophthalmic dose). In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day. </p>
<p>The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in humans. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin. </p>
<p>The following tests for mutagenic potential were negative for dorzolamide: (1) <span class="Italics">in vivo</span> (mouse) cytogenetic assay; (2) <span class="Italics">in vitro</span> chromosomal aberration assay; (3) alkaline elution assay; (4) V-79 assay; and (5) Ames test. </p>
<p>Timolol maleate was devoid of mutagenic potential when tested <span class="Italics">in vivo</span> (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and <span class="Italics">in vitro</span> in a neoplastic cell transformation assay (up to 100 μg/mL). In Ames tests the highest concentrations of timolol employed, 5,000 or 10,000 μg/plate, were associated with statistically significant elevations of revertants observed with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100 (in seven replicate assays), but not in the remaining three <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. In the assays with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test. </p>
<p>Reproduction and fertility studies in rats with either timolol maleate or dorzolamide hydrochloride demonstrated no adverse effect on male or female fertility at doses up to approximately 100 times the systemic exposure following the maximum recommended human ophthalmic dose.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_48acd91e-c938-47ce-b2dd-65ae7b6c5e23"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_ed214054-73e4-44bf-a17a-a63e552095db"></a><a name="section-6.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<p class="First">Pregnancy Category C. Developmental toxicity studies with dorzolamide hydrochloride in rabbits at oral doses of ≥2.5 mg/kg/day (31 times the recommended human ophthalmic dose) revealed malformations of the vertebral bodies. These malformations occurred at doses that caused <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> with decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in dams and decreased fetal weights. No treatment-related malformations were seen at 1.0 mg/kg/day (13 times the recommended human ophthalmic dose). </p>
<p><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity. </p>
<p>There are no adequate and well-controlled studies in pregnant women. COSOPT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_5baa492d-6d9d-48c6-a6dc-460a04e7e4a4"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether dorzolamide is excreted in human milk. Timolol maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from COSOPT in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_fea677d1-8a5e-4d9e-ac47-fa71e0e6ae67"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of dorzolamide hydrochloride ophthalmic solution and timolol maleate ophthalmic solution have been established when administered individually in pediatric patients aged 2 years and older. Use of these drug products in these children is supported by evidence from adequate and well-controlled studies in children and adults. Safety and efficacy in pediatric patients below the age of 2 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_ad387e8c-319a-4cde-8171-a120c527844f"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_6ca0070a-7ad0-4e21-8c0e-7e4444b01e66"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">COSOPT was evaluated for safety in 1035 patients with elevated intraocular pressure treated for open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>. Approximately 5% of all patients discontinued therapy with COSOPT because of adverse reactions. The most frequently reported adverse events were <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> (bitter, sour, or unusual taste) or ocular burning and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> in up to 30% of patients. <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">Conjunctival hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">superficial punctate keratitis</span> or <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye itching</span> were reported between 5-15% of patients. The following adverse events were reported in 1-5% of patients: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">cloudy vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctival discharge</span>, <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">conjunctival edema</span>, <span class="product-label-link" type="condition" conceptid="4224417" conceptname="Conjunctival follicle">conjunctival follicles</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival injection</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="4080997" conceptname="Corneal epithelial staining pattern">corneal staining</span>, cortical <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lens opacity</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dryness of eyes</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, eye debris, <span class="product-label-link" type="condition" conceptid="4080696" conceptname="Discharge from eye">eye discharge</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, eye tearing, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, eyelid <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, eyelid exudate/scales, eyelid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, foreign body sensation, glaucomatous cupping, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, lens nucleus coloration, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lens opacity</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, nuclear <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lens opacity</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, post-<span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">subcapsular cataract</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="4202518" conceptname="Vitreous detachment">vitreous detachment</span>. </p>
<p>The following adverse events have occurred either at low incidence (&lt;1%) during clinical trials or have been reported during the use of COSOPT in clinical practice where these events were reported voluntarily from a population of unknown size and frequency of occurrence cannot be determined precisely. They have been chosen for inclusion based on factors such as seriousness, frequency of reporting, possible causal connection to COSOPT, or a combination of these factors: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">choroidal detachment</span> following filtration surgery (see <a href="#i4i_precautions_general_id_be36cb4b-3e1c-4770-b6fb-352d0a707e87">PRECAUTIONS, General</a>), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="79873" conceptname="Urolith">urolithiasis</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p>Other adverse reactions that have been reported with the individual components are listed below: </p>
<p><span class="Italics">Dorzolamide </span>—<span class="Italics"> Allergic/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:  </span>Signs and symptoms of local reactions including palpebral reactions and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="Italics">Skin/Mucous Membranes:</span> <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>; <span class="Italics">Special Senses:</span> Eyelid crusting, signs and symptoms of ocular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, and transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span>. </p>
<p><span class="Italics">Timolol (ocular administration) </span>—<span class="Italics"> Body as a Whole:  </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="Italics">Cardiovascular: </span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, worsening of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span>, Raynaud's phenomenon, and <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold hands</span> and feet; <span class="Italics">Digestive: </span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; <span class="Italics">Immunologic:</span> <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span>; <span class="Italics">Nervous System/Psychiatric: </span> Increase in signs and symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, behavioral changes and <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>; <span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, psoriasiform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">exacerbation of psoriasis</span>; <span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span> Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and localized and generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="Italics">Respiratory: </span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (predominantly in patients with pre-existing bronchospastic disease); <span class="Italics">Endocrine:</span> Masked symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in diabetic patients (see <a href="#i4i_warnings_id_c8db6756-8ec1-49b4-91fe-9a0955ca3715">WARNINGS</a>); <span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">Ptosis</span>, decreased corneal sensitivity, <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> including refractive changes and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, pseudopemphigoid, and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; <span class="Italics">Urogenital: </span> <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">Retroperitoneal fibrosis</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>, and Peyronie's disease; <span class="Italics">Musculoskeletal</span>: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>. </p>
<p>The following additional adverse effects have been reported in clinical experience with ORAL timolol maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic timolol maleate: <span class="Italics">Allergic: </span>Erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> with <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>; <span class="Italics">Body as a Whole:</span> Extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, decreased exercise tolerance, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>; <span class="Italics">Cardiovascular: </span> Worsening of <span class="product-label-link" type="condition" conceptid="4109870" conceptname="Arterial insufficiency">arterial insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>; <span class="Italics">Digestive: </span> <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">Gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>; <span class="Italics">Hematologic: </span> Nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>; <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; <span class="Italics">Endocrine: </span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>; <span class="Italics">Skin: </span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; <span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>; <span class="Italics">Nervous System/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, local <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, diminished concentration, reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>, an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium, and decreased performance on neuropsychometrics; <span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span>, <span class="product-label-link" type="condition" conceptid="4279071" conceptname="Obstruction of bronchus">bronchial obstruction</span>; <span class="Italics">Urogenital:</span> Urination difficulties.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_b04c8472-045e-48ec-a7ef-1cb0aa7df892"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There are no human data available on overdosage with COSOPT. </p>
<p>Symptoms consistent with systemic administration of beta-blockers or carbonic anhydrase inhibitors may occur, including <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, development of an acidotic state, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and possible central nervous system effects. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored (see also <a href="#i4i_adverse_effects_id_6ca0070a-7ad0-4e21-8c0e-7e4444b01e66">ADVERSE REACTIONS</a>). </p>
<p>A study of patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> showed that timolol did not dialyze readily.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b97f9732-b806-4b4f-bb1d-0dc5e19280b4"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose is one drop of COSOPT in the affected eye(s) two times daily. </p>
<p>If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart (see also <a href="#i4i_interactions_id_495f23a9-0cac-4e63-a958-764dba6d41fd">PRECAUTIONS, Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_64f35995-efab-4223-ae71-4ac9303a0290"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">COSOPT Ophthalmic Solution is a clear, colorless to nearly colorless, slightly viscous solution. </p>
<p>No. 3628 — COSOPT Ophthalmic Solution is supplied in an OCUMETER<span class="Sup">®</span> PLUS container, a white, translucent, HDPE plastic ophthalmic dispenser with a controlled drop tip and a white polystyrene cap with dark blue label as follows: </p>
<p><span class="Bold">NDC</span> 0006-3628-36, 10 mL in an 18 mL capacity bottle.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_a0ea3df2-5a4c-40ba-980d-a9ae5af773e2"></a><a name="section-10.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store COSOPT at 15-30°C (59-86°F). Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b975bd83-2221-4f5e-aeaf-69388673fd4b"></a><a name="section-11"></a><p></p>
<h1>INSTRUCTIONS FOR USE</h1>
<p class="First">Please follow these instructions carefully when using COSOPT. Use COSOPT as prescribed by your doctor. </p>
<ol>
<li>If you use other topically applied ophthalmic medications, they should be administered at least 10 minutes before or after COSOPT.<br><br>
</li>
<li>Wash hands before each use.<br><br>
</li>
<li>Before using the medication for the first time, be sure the Safety Strip on the front of the bottle is unbroken. A gap between the bottle and the cap is normal for an unopened bottle.<br><div class="Figure"><img alt="image for step 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-03.jpg"></div>
</li>
<li>Tear off the Safety Strip to break the seal.<br><div class="Figure"><img alt="image for step 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-04.jpg"></div>
</li>
<li>To open the bottle, unscrew the cap by turning as indicated by the arrows on the top of the cap. Do not pull the cap directly up and away from the bottle. Pulling the cap directly up will prevent your dispenser from operating properly.<br><div class="Figure"><img alt="image for step 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-05.jpg"></div>
</li>
<li> Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and your eye.<br><div class="Figure"><img alt="image for step 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-06.jpg"></div>
</li>
<li>Invert the bottle, and press lightly with the thumb or index finger over the "Finger Push Area" (as shown) until a single drop is dispensed into the eye as directed by your doctor.<br><div class="Figure"><img alt="image for step 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-07.jpg"></div>
<br>DO NOT TOUCH YOUR EYE OR EYELID WITH THE DROPPER TIP. <br><br>OPHTHALMIC MEDICATIONS, IF HANDLED IMPROPERLY, CAN BECOME CONTAMINATED BY COMMON BACTERIA KNOWN TO CAUSE <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">EYE INFECTIONS</span>. SERIOUS DAMAGE TO THE EYE AND SUBSEQUENT <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">LOSS OF VISION</span> MAY RESULT FROM USING CONTAMINATED OPHTHALMIC MEDICATIONS. IF YOU THINK YOUR MEDICATION MAY BE CONTAMINATED, OR IF YOU DEVELOP AN <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">EYE INFECTION</span>, CONTACT YOUR DOCTOR IMMEDIATELY CONCERNING CONTINUED USE OF THIS BOTTLE.<br><br>
</li>
<li>If drop dispensing is difficult after opening for the first time, replace the cap on the bottle and tighten (DO NOT OVERTIGHTEN) and then remove by turning the cap in the opposite direction as indicated by the arrows on the top of the cap.<br><br>
</li>
<li>Repeat steps 6 &amp; 7 with the other eye if instructed to do so by your doctor.<br><br>
</li>
<li>After using COSOPT, press a finger into the corner of your eye, by the nose (as shown) for 2 minutes. This helps keep COSOPT in your eye.<div class="Figure"><img alt="image for step 10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-08.jpg"></div>
</li>
<li>Replace the cap by turning until it is firmly touching the bottle. The arrow on the left side of the cap must be aligned with the arrow on the left side of the bottle label for proper closure. Do not overtighten or you may damage the bottle and cap.<br><br>
</li>
<li>The dispenser tip is designed to provide a single drop; therefore, do NOT enlarge the hole of the dispenser tip.<br><br>
</li>
<li>After you have used all doses, there will be some COSOPT left in the bottle. You should not be concerned since an extra amount of COSOPT has been added and you will get the full amount of COSOPT that your doctor prescribed. Do not attempt to remove the excess medicine from the bottle.</li>
</ol>
<p>WARNING: Keep out of reach of children.</p>
<p>If you have any questions about the use of COSOPT, please consult your doctor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Manuf. for: Merck Sharp &amp; Dohme Corp., a subsidiary of <br><span class="Bold">MERCK &amp; CO., INC., </span>Whitehouse Station, NJ 08889, USA</p>
<p>By: Laboratoires Merck Sharp &amp; Dohme-Chibret <br>Clermont Ferrand Cedex 9, 63963, France </p>
<p>Revised: 11/2012</p>
<p>USPI-OS-0507A1210R007</p>
<p>Copyright © 1998, 2004, 2005 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_089145fd-4116-45ab-9312-3e8008c28bf3"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">Patient Information about <br>COSOPT<span class="Sup">®</span></span><span class="Bold"> (dorzolamide hydrochloride–timolol maleate ophthalmic solution) <br>COSOPT (pronounced "CO-sopt")</span></p>
<p>Read this information before you start using COSOPT and each time you refill your prescription. This is in case any information has changed. This leaflet provides a summary of certain information about COSOPT. Your doctor or pharmacist can give you more complete information about COSOPT. This leaflet does not take the place of careful discussions with your doctor. You and your doctor should discuss COSOPT when you start using your medicine and at regular checkups. Only your doctor can prescribe COSOPT for you.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_31ad80a9-76e3-48aa-b6c9-2e6f02f16009"></a><a name="section-13.1"></a><p></p>
<h2>What is COSOPT?</h2>
<p class="First">COSOPT is an eyedrop. It contains dorzolamide hydrochloride, which is an ophthalmic carbonic anhydrase inhibiting drug. It also contains timolol maleate, which is a beta-blocking drug. Both drugs work to lower pressure in the eye, but in different ways. </p>
<p>COSOPT is a medicine for lowering pressure in the eye in people with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>. It is used when a beta-blocker eyedrop alone is not adequate to control eye pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_837b2d6d-7d41-4481-bd81-b08945c43da1"></a><a name="section-13.2"></a><p></p>
<h2>What should I know about high pressure in the eye?</h2>
<p class="First">People with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> have pressures in one or both of their eye(s) that are too high for them.</p>
<p>High pressure in the eye may damage the optic nerve. This may lead to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> and possible <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>. There generally are few symptoms that you can feel to tell you whether you have high pressure within your eye. Your doctor needs to examine your eyes to determine this. If you have high pressure in your eye, you will need your pressure checked and your eyes examined regularly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4a56fc5b-4297-4b92-a1e3-6cc17acf075f"></a><a name="section-13.3"></a><p></p>
<h2>Who should not use COSOPT?</h2>
<p class="First">Do not use COSOPT if you have:</p>
<ul>
<li>or have ever had certain serious breathing problems such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>,</li>
<li>severe lung problems (such as <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>),</li>
<li>heart problems, including slow or irregular heartbeat or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>,</li>
<li>allergies to any of its ingredients. See the list at the end of the leaflet.</li>
</ul>
<p>If you are not sure whether you should use COSOPT, contact your doctor or pharmacist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24475d50-037b-4a20-91cb-a96ff85c3a93"></a><a name="section-13.4"></a><p></p>
<h2>What should I tell my doctor before and during treatment with COSOPT?</h2>
<p class="First">Tell your doctor:</p>
<ul>
<li>if you are pregnant or plan to become pregnant,</li>
<li>if you are breastfeeding or intend to breastfeed,</li>
<li>about any medical problems you have now or had in the past, especially heart problems or breathing problems including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>,</li>
<li>if you now have or had in the past kidney or liver problems,</li>
<li>if you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, thyroid disease or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>,</li>
<li>if you have poor blood circulation problems (such as Raynaud's syndrome)</li>
<li>about all medicines that you are taking or plan to take, including those you can get without a prescription,</li>
<li>about any allergies including allergies to any medications, especially sulfa drugs,</li>
<li>if you develop an <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infection</span>, develop a red or swollen eye or eyelid, receive an eye injury, have eye surgery, or develop new or worsening eye symptoms,</li>
<li>if you plan on having any type of surgery.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ffd9ae8d-f69b-46a5-896f-3b13a9fb8588"></a><a name="section-13.5"></a><p></p>
<h2>How should I use COSOPT?</h2>
<p class="First">COSOPT is an eyedrop. The usual dose is one drop in the morning and one drop in the evening. Your doctor will tell you if just one or both eyes are to be treated. </p>
<p>If you are using COSOPT with another eyedrop, the eyedrops should be used at least 10 minutes apart. It is very important to use your medication exactly as directed by your doctor. If you stop using your medicine, contact your doctor immediately. </p>
<p>COSOPT contains a preservative called benzalkonium chloride. This preservative may be absorbed by soft contact lenses. Contact lenses should be removed before using COSOPT. The lenses can be placed back into your eyes 15 minutes after using the eyedrops. </p>
<p>Do not allow the tip of the bottle to touch the eye or areas around the eye. The bottle may become contaminated with bacteria. This can cause <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infections</span> leading to serious damage to the eye, even <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>. Keep the tip of the bottle away from contact with any surface to avoid contamination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bab7eaa7-ac44-40c9-b139-697286a23e94"></a><a name="section-13.6"></a><p></p>
<h2>INSTRUCTIONS FOR USE</h2>
<p class="First">Please follow these instructions carefully when using COSOPT. Use COSOPT as prescribed by your doctor. </p>
<ol>
<li>If you use other topically applied ophthalmic medications, they should be administered at least 10 minutes before or after COSOPT.<br><br>
</li>
<li>Wash hands before each use.<br><br>
</li>
<li>Before using the medication for the first time, be sure the Safety Strip on the front of the bottle is unbroken. A gap between the bottle and the cap is normal for an unopened bottle.<br><div class="Figure"><img alt="patient package insert image for step 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-03.jpg"></div>
</li>
<li>Tear off the Safety Strip to break the seal.<br><div class="Figure"><img alt="patient package insert image for step 4 " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-04.jpg"></div>
</li>
<li>To open the bottle, unscrew the cap by turning as indicated by the arrows on the top of the cap. Do not pull the cap directly up and away from the bottle. Pulling the cap directly up will prevent your dispenser from operating properly.<br><div class="Figure"><img alt="patient package insert image for step 5 " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-05.jpg"></div>
</li>
<li> Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and your eye.<br><div class="Figure"><img alt="patient package insert image for step 6 " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-06.jpg"></div>
</li>
<li>Invert the bottle, and press lightly with the thumb or index finger over the "Finger Push Area" (as shown) until a single drop is dispensed into the eye as directed by your doctor.<br><div class="Figure"><img alt="patient package insert image for step 7 " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-07.jpg"></div>
<br>DO NOT TOUCH YOUR EYE OR EYELID WITH THE DROPPER TIP. <br><br>OPHTHALMIC MEDICATIONS, IF HANDLED IMPROPERLY, CAN BECOME CONTAMINATED BY COMMON BACTERIA KNOWN TO CAUSE <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">EYE INFECTIONS</span>. SERIOUS DAMAGE TO THE EYE AND SUBSEQUENT <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">LOSS OF VISION</span> MAY RESULT FROM USING CONTAMINATED OPHTHALMIC MEDICATIONS. IF YOU THINK YOUR MEDICATION MAY BE CONTAMINATED, OR IF YOU DEVELOP AN <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">EYE INFECTION</span>, CONTACT YOUR DOCTOR IMMEDIATELY CONCERNING CONTINUED USE OF THIS BOTTLE.<br><br>
</li>
<li>If drop dispensing is difficult after opening for the first time, replace the cap on the bottle and tighten (DO NOT OVERTIGHTEN) and then remove by turning the cap in the opposite direction as indicated by the arrows on the top of the cap.<br><br>
</li>
<li>Repeat steps 6 &amp; 7 with the other eye if instructed to do so by your doctor.<br><br>
</li>
<li>After using COSOPT, press a finger into the corner of your eye, by the nose (as shown) for 2 minutes. This helps keep COSOPT in your eye.<div class="Figure"><img alt="image for step 10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-08.jpg"></div>
</li>
<li>Replace the cap by turning until it is firmly touching the bottle. The arrow on the left side of the cap must be aligned with the arrow on the left side of the bottle label for proper closure. Do not overtighten or you may damage the bottle and cap.<br><br>
</li>
<li>The dispenser tip is designed to provide a single drop; therefore, do NOT enlarge the hole of the dispenser tip.<br><br>
</li>
<li>After you have used all doses, there will be some COSOPT left in the bottle. You should not be concerned since an extra amount of COSOPT has been added and you will get the full amount of COSOPT that your doctor prescribed. Do not attempt to remove the excess medicine from the bottle.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2de2fbf-0ff1-43cc-8cc6-a81cfbc7e867"></a><a name="section-13.7"></a><p></p>
<h2>Can I use COSOPT with other medicines?</h2>
<p class="First">Tell your doctor or pharmacist about all drugs that you are using or plan to use. This includes other eyedrops and drugs obtained without a prescription. This is particularly important if you are taking medicine to lower blood pressure or to treat heart disease, medicines to treat <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or if you are taking large doses of aspirin. </p>
<p>Ask your doctor's advice about taking COSOPT if you are also using:</p>
<ul>
<li>oral carbonic anhydrase inhibitors (for example, acetazolamide, Diamox®)</li>
<li>oral beta-blockers (for example, propranolol, Inderal®)</li>
<li>calcium antagonists (for example, nifedipine, Procardia®)</li>
<li>catecholamine-depleting drugs (for example, reserpine)</li>
<li>digitalis in combination with calcium antagonists (for example, Lanoxin® with Procardia®)</li>
<li>quinidine (for example, Cardioquin®)</li>
<li>clonidine (for example, Catapres®)</li>
<li>injectable epinephrine (for example, EpiPen®)</li>
<li>certain antidepressants (for example Prozac®)</li>
</ul>
<p>Your doctor or pharmacist can tell you if any of the drugs you are using are in the above list.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b8004d5-3db0-4f78-9424-b072358d0c5a"></a><a name="section-13.8"></a><p></p>
<h2>What are the possible side effects of COSOPT?</h2>
<p class="First">Any medicine may have unintended or undesirable effects. These are called side effects. Side effects may not occur, but if they do occur, you may need medical attention. The most common side effects you may experience are: </p>
<ul>
<li>eye symptoms such as burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the eye(s), <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, tearing or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</li>
<li>a bitter, sour or unusual taste after putting in your eyedrops.</li>
</ul>
<p>Other side effects may occur rarely, and some of these may be serious. Tell your doctor right away if you experience:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li>visual changes</li>
<li>an irregular heartbeat and/or a slowing of your heart rate</li>
<li>severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
</ul>
<p>The above list is NOT a complete list of side effects reported with COSOPT. Your doctor can discuss with you a more complete list of side effects. Please tell your doctor [or pharmacist] promptly about any of these or any other unusual symptom.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_61d63d28-7ea1-4b24-b899-1d1838237e04"></a><a name="section-13.9"></a><p></p>
<h2>What should I do in case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>?</h2>
<p class="First">If you swallow the contents of the bottle, contact your doctor immediately. Among other effects, you may feel light-headed, have <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, or feel your heart rate has slowed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e82c096f-f809-45a0-a745-10ecd42d2025"></a><a name="section-13.10"></a><p></p>
<h2>How should I store COSOPT?</h2>
<p class="First">Keep your medicine in a safe place where children cannot reach it. Store COSOPT at room temperature 15-30°C (59-86°F). Protect the bottle from light. Do not use your medicine after the expiration date on the bottle.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c947310-9044-464a-8ab0-f105eb0f2a22"></a><a name="section-13.11"></a><p></p>
<h2>What else should I know about COSOPT?</h2>
<p class="First">Do not use COSOPT for a condition for which it was not prescribed. Do not give COSOPT to other people, even if they have the same condition you have. It may harm them.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_34a5faa2-fca9-49ae-af73-89beb170bd81"></a><a name="section-13.12"></a><p></p>
<h2>Inactive ingredients:</h2>
<p class="First">The inactive ingredients of COSOPT are sodium citrate, hydroxyethylcellulose, sodium hydroxide, mannitol, water for injection and benzalkonium chloride added as a preservative. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.13"></a><p></p>
<p class="First">Manuf. for: Merck Sharp &amp; Dohme Corp., a subsidiary of <br><span class="Bold">MERCK &amp; CO., INC., </span>Whitehouse Station, NJ 08889, USA</p>
<p>By: Laboratoires Merck Sharp &amp; Dohme-Chibret<br>Clermont Ferrand Cedex 9, 63963, France</p>
<p>Revised: 11/2012</p>
<p>USPPI-OS-0507A1210R007</p>
<p>Copyright © 2005 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_63c651e7-edd0-433b-b8ab-16512c9b6ce7"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mL Bottle Carton</h1>
<p class="First"><span class="Bold">NDC 0006-3628-36</span></p>
<p><span class="Bold">10 mL<br>OCUMETER</span><span class="Sup">®</span><span class="Bold"> PLUS<br>OPHTHALMIC DISPENSER<br>STERILE</span><br><span class="Bold">OPHTHALMIC SOLUTION</span></p>
<p><span class="Bold">COSOPT</span><span class="Sup">®</span><br><span class="Bold">(DORZOLAMIDE<br> HYDROCHLORIDE -<br>TIMOLOL MALEATE<br>OPHTHALMIC SOLUTION)</span></p>
<p><span class="Bold">(Dorzolamide Hydrochloride<br>22.3 mg/mL<br>Timolol Maleate 6.8 mg/mL)</span></p>
<p><span class="Bold">Rx only</span></p>
<p><img alt="PRINCIPAL DISPLAY PANEL - 10 mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3092b5b7-ef53-480c-968a-09c9c5df7bf8&amp;name=cosopt-09.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COSOPT 		
					</strong><br><span class="contentTableReg">dorzolamide hydrochloride and timolol maleate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0006-3628</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DORZOLAMIDE HYDROCHLORIDE</strong> (DORZOLAMIDE) </td>
<td class="formItem">DORZOLAMIDE</td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>TIMOLOL MALEATE</strong> (TIMOLOL ANHYDROUS) </td>
<td class="formItem">TIMOLOL ANHYDROUS</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0006-3628-36</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020869</td>
<td class="formItem">04/07/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merck Sharp &amp; Dohme Corp.
							(001317601)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Laboratoires Merck, Sharp &amp; Dohme-Chibret</td>
<td class="formItem"></td>
<td class="formItem">493743686</td>
<td class="formItem">MANUFACTURE(0006-3628), PACK(0006-3628)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Merck Sharp &amp; Dohme Corp.</td>
<td class="formItem"></td>
<td class="formItem">001705110</td>
<td class="formItem">API MANUFACTURE(0006-3628)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ZACH SYSTEM SPA</td>
<td class="formItem"></td>
<td class="formItem">517259979</td>
<td class="formItem">API MANUFACTURE(0006-3628)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Merck Sharp &amp; Dohme de Puerto Rico, Inc.</td>
<td class="formItem"></td>
<td class="formItem">168378490</td>
<td class="formItem">API MANUFACTURE(0006-3628)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Laboratoires Merck Sharp &amp; Dohme-Chibret</td>
<td class="formItem"></td>
<td class="formItem">493743678</td>
<td class="formItem">API MANUFACTURE(0006-3628)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0e120c24-ff81-4433-a0bd-c4390047f6bd</div>
<div>Set id: 3092b5b7-ef53-480c-968a-09c9c5df7bf8</div>
<div>Version: 8</div>
<div>Effective Time: 20121116</div>
</div>
</div> <div class="DistributorName">Merck Sharp &amp; Dohme Corp.</div></p>
</body></html>
